Diagnóstico y tratamiento de aldosteronismo primario

Sánchez Turcios, Reinaldo Alberto

Servicios Personalizados

Revista

Articulo

Indicadores

Citado por SciELO
Accesos

Links relacionados

Similares en SciELO

Otros
Otros

Permalink

Revista mexicana de cardiología

versión impresa ISSN 0188-2198

Rev. Mex. Cardiol vol.26 no.3 México jul./sep. 2015

Review

Diagnosis and management of primary aldosteronism

Diagnóstico y tratamiento de aldosteronismo primario

Reinaldo Alberto Sánchez Turcios*

* Endocrinologist, MSc Pharmacology. General Hospital Milpa Alta, México, D.F.

Correspondence to:
Reinaldo Alberto Sánchez Turcios
Tepic Núm. 113-610,
Col. Roma Sur,
Del. Cuauhtémoc, 06760, México, Distrito Federal, México.
Tel. 015552648061
Cel. 0445543508824
E-mail: rturcios@live.com.mx

Recibido: 27/07/2015
Aceptado: 25/08/2015

ABSTRACT

Primary hyperaldosteronism is a set of pathologies that share an excessive biosynthesis, and sustained autonomous aldosterone hypersecretion. This condition is mainly manifested clinically by: systemic arterial hypertension, hypokalemia, and metabolic alkalosis. Biological hypertension behavior is generally severe and refractory to the usual antihypertensive medication and it is the most frequent cause of secondary systemic arterial hypertension. Their biochemical characteristics are: plasma aldosterone concentration (PAC) > 20 ng/dL, plasma renin activity (PRA) < 0.5 ng/mL/h, undetectable and/or low plasmatic renin concentration, and hypokalemia in 50% of the cases. Diagnosis is established when PAC/PRA ratio is ≥ 50. Location tests include: computed tomography, magnetic resonance imaging, and aldosterone measurement in right and left adrenal veins with a gradient ≥ 4, confirming catheterization of adrenal veins with cortisol concentration ratio at least 5:1 in relation to inferior vena cava. It is preferred a surgical treatment with laparoscopy in most cases, though some physicians consider, depending on the tumor size, a pharmacological treatment with mineralocorticoid receptor antagonists.

Key words: Primary aldosteronism diagnosis, systemic arterial hypertension.

RESUMEN

El hiperaldosteronismo primario es un conjunto de patologías que comparten la biosíntesis excesiva e hipersecreción sostenida y autónoma de aldosterona. Clínicamente se manifiesta principalmente por: hipertensión arterial sistémica, hipokalemia y alcalosis metabólica. La conducta biológica de la hipertensión generalmente es severa y refractaria a los antihipertensivos habituales. Es la causa más frecuente de hipertensión arterial sistémica secundaria. Sus características bioquímicas son: PAC > 20 ng/dL, PRA < 0.5 ng/mL/h, concentración de renina plasmática indetectable y/o baja e hipokalemia en el 50% de los casos. El diagnóstico se establece cuando el cociente PAC/PRA ≥ 50. Los estudios de localización son: tomografía computarizada, resonancia magnética y la concentración de aldosterona en las venas adrenales derecha e izquierda con gradiente ≥ 4 habiendo confirmado la correcta cateterización con la concentración de cortisol en venas adrenales y en vena cava inferior con proporción mínima de 5:1. Su tratamiento es quirúrgico, preferentemente a través de laparoscopía, aunque otros consideran que, según las dimensiones del tumor, puede ser mediante laparotomía para una minoría de casos. El tratamiento farmacológico es con antagonistas de los receptores de mineralocorticoides.

Palabras clave: Diagnóstico de aldosteronismo primario, hipertensión arterial sistémica.

INTRODUCTION

Primary hyperaldosteronism (PH) is a group of pathologies characterized by an increased and sustained, autonomous aldosterone secretion caused by hyperplasia and/or neoplasia in the zona glomerulosa of the adrenal cortex. It is the most common etiology of secondary systemic arterial hypertension and it is found in ≥ 12% of the cases considered as primary systemic arterial hypertension.¹ The prevalence of PH increases in population subgroups with the following factors: severe hypertension or refractory hypertension (20-23%),^2,3 hypertension and hypokalemia, younger than forty year old patients with a history of cerebrovascular disease, younger than twenty year old hypertensive patients, first degree relative with adrenal incidentalomas. PH is a group of pathologies that damage cardiovascular, renal and cerebrovascular structures even with an optimal hypertension control, and a biochemical constellation which consists of: plasma aldosterone concentration (PAC) > 20 ng/dL, plasmatic renin activity (PRA) < 0.5 ng/mL/h, when plasmatic renin concentration is low and sometimes non-detectable. It has been associated with hypokalemia and metabolic alkalosis. Hyperaldosterism generating hypertension has a greater likelihood to be complicated with cardiovascular, renal, cerebrovascular morbidity, and mortality.

ETIOLOGY

Primary aldosteronism⁴

1. Bilateral idiopathic hyperplasia (BIH) 60% of cases.

2. Aldosterone-producing adenoma (APA) 35% of cases.

3 Primary adrenal hyperplasia 2% of cases.

4. Aldosterone-producing adrenocortical carcinoma < 1% of cases.

5. Familial hyperaldosteronism (FH).

(a) Glucocorticoid-remediable aldosteronism (FH type I) < 1% of cases.

(b) FH type II (APA or BIH) < 2% of cases.

6. Ectopic aldosterone producing adenoma or carcinoma < 0.1% of cases.

DIAGNOSIS PROTOCOL

First stage. If there is hypokalemia, the first step will be to correct this condition. It is fundamental to do it before start diagnosis. The procedure is to increase NaCl intake up to 5 g daily; another option is to administrate orally 2-one gram NaCl tablets three times a day to achieve a total of 6 g, and then determine serum electrolytes. It is important to note that if hypokalemia remains, potassium chloride should be administered; if potassium is within the normal range, withhold all medications that substantially affect PRA, PAC/PRA, and the plasma renin for 2-4 weeks. Collect sample in the morning (preferably at 8:00 a.m.), 2-4 hours after patient being up and ambulating and determine: PAC > 20 ng/dL, PRA < 0.5 ng/dL and, plasma renin concentration (separate plasma after 30 minutes of collection). The ratio PAC/PRA ≥ 50 is diagnostic,^5,6 from 49 to 25 without other criteria, probable diagnosis; if there is normokalemia withhold medications for 2-4 weeks and carry out the above mentioned tests.

Step 2

A) Fludrocortisone test: administer 0.1 mg fludrocortisone each 6 h/4 days with KCL supplement, collect sample for upright PRA and PAC at 10:00 a.m. on day fourth of the test.⁷

Positive test: PRA < 1 ng/mL/h and PAC > 6 ng/dL.

B) Infusion of sodium chloride at 0.9% test: have the patient in dorsal decubitus position for an hour before, and then administer to the patient a 2 sodium chloride liters of 0.9% I.V. over fourth hours, starting at 08:00-12:00 hours. Collect sample for electrolytes, PAC, PRA, renin and cortisol before and after saline infusion.

Post infusion, if PAC < 5 ng/dL the diagnosis it is unlikely. If PAC > 10 ng/dL levels are within this range, diagnosis is probable; values between 5 and 10 ng/dL are indeterminated.^7-10

C) Captopril test: Patient sits or stands for one hour before the test. Administer captopril 25-50 mg orally; patient remains sitting for, at least, one hour. Blood samples are drawn for measurement of PRA, PAC, and cortisol basal, and at 1 or 2 h after challenge, with the patient seated during this period. Plasma aldosterone is normally suppressed by captopril (30%). In patients with PH, the PAC/PRA remains elevated, and PRA remains suppressed. Differences may be seen between patients with APA and those with BIH. However, some decrease of aldosterone levels is occasionally seen in BIH.^11,12 Another interpretation option: take plasma samples of PAC, PRA levels before and 1-2 hours after captopril administration. If PAC > 12 ng/dL and PRA < 0.5 ng/mL/hour the test is diagnostic.¹³

LOCATION PROCEDURES

1. Adrenal computed tomography (CT): patient must fast for 8 hours before the procedure.⁷

2. Adrenal magnetic resonance imaging (MRI). Fasting for 8 hours before the test is usually recommended.^14,15

3. Adrenal vein sampling (AVS) of aldosterone.¹⁶ I.V. catheters are placed in right¹⁷ and left adrenal veins and distal inferior vena cava (IVC) through the percutaneous femoral vein punction.¹⁸

b.Administer synthetic adreno corticotrophic hormone (ACTH)-250 mcg bolus injection aftersuccessful cannulation of adrenal veins, or 50 μg/hour continuous I.V. infusion,¹⁹ starting 30 minutes before the procedure.

c. Collect blood sample for PAC and cortisol levels from both adrenal veins and IVC before and during continuous I.V. infusion, or after bolus injection of ACTH.

d. The right and left adrenal vein PACs ratio with their respective cortisol concentrations, corrects for dilution effects of the inferior cava vein.

e. A cutoff of the aldosterone ratio from high side to low side more than 4:1 is used to indicate unilateral aldosterone excess;²⁰ a ratio less than 3:1 is suggestive of bilateral aldosterone hypersecretion.²¹

PRIMARY ALDOSTERONISM MANAGEMENT

Pharmacotherapy

1. Spironolactone is a nonselective aldosterone receptor antagonist that competitively inhibits the binding of aldosterone to the mineralocorticoid receptor. The therapeutic dose range is usually between 75 to 225 mg once daily.¹⁹ Adverse effects are gynecomastia (6.9% to 52%) and erectile dysfunction in men, hyperkalemia, and renal dysfunction.²²

2. Eplerenone is a selective aldosterone receptor antagonist with 60% of spironolactone action. Therapeutic doses are within 100 to 300 mg once daily, using a progression scheme to obtain the necessary effect. It does not have antiandrogen nor progesterone agonist effect, resulting in gynecomastia (1%) and hyperkalemia (21.1%) and renal dysfunction (6.5%).²³

3. Amiloride potassium-sparing diuretic. Starting with 5 mg a day, which may be increased to 10 mg daily; in sceneries when hyperkalemia persists, it may be raised to 20 mg a day. Adverse effects are hyperkalemia, renal dysfunction, nausea, vomiting, diarrhea, and loss of appetite.²⁴

4. Dexamethasone, whose dose is 0.125-0.25 mg/day, suppresses ACTH for glucocorticoid remediable aldosteronism. Adverse effects: increased appetite, restlessness, Cushing syndrome, o |steoporosis, impaired linear growth in children.⁷

Surgical treatment

Approximately 30% of all PH patients has clear lateralization of aldosterone production and will benefit from unilateral adrenalectomy.^25-27 Laparoscopic adrenalectomy is the most suitable therapy for APA or unilateral adrenal hyperplasia. Complications may be developed after surgery: hemorrhage and suppression of the renin-angiotensin axis that causes transient postoperative hypoaldosteronism; then a liberal sodium diet should be allowed to prevent hyperkalemia after surgery.²⁸ An I.V. infusion of 0.9% sodium chloride every 8 to 12 hours may be necessary to avoid postoperative intravascular volume depletion. All antihypertensive medications, especially spironolactone and amiloride, should be withheld and other antihypertensive medications may be cautiously reinstituted as needed within a few days.²⁹

Postoperative evolution: assess remaining adrenal gland. Postoperative PRA and aldosterone-to-renin ratio (ARR) are commonly repeated. Some authors recommend assessment of the autonomous function of the remaining adrenal gland in three months. These authors also periodically obtained CT scan in their patients at 1 to 3 yearly intervals, because they have observed that the remaining adrenal gland could slowly increase in size, become nodular, or develop adenoma after surgery.²⁹

PROGNOSIS

Approximately 33% of APA patients improved or have resolution of secondary hypertension and hypokalemia with normal PAC and PRA after unilateral adrenalectomy. Arterial hypertension is normally resolved within 1 to 6 months, and patients with persistent or residual arterial hypertension, who are likely to be older, require more than two antihypertensive medicaments before and during surgery.³⁰

FOLLOW UP

During the first year of follow-up, patients must be assessed every two months for PAC, PRA electrolytes, creatinine depuration, proteinuria, urinalysis, and having strict clinical evaluation. In case of controlling the above mentioned values, follow-up assessment must be carried out every 6 months for life. But if there is renal and/or cardiovascular deterioration, one should form a specialist team (nephrologists, cardiologists, endocrinologist, radiologist and gastro surgeons with laparoscopic experience) to improve patient's care. Since aldosterone is a toxin with deep deleterious effects in the renal and cardiovascular system; in some cases, renal function diminishes once the tumor has been excised due to pathological consequences of the aldosterone toxicity.

CONCLUSIONS

• Severe systemic hypertension (>160 mmHg systolic or >100 mmHg diastolic) in patients younger than 30 years old should be studied for primary hyperaldosterism.

• Systemic arterial hypertension resistant to antihypertensive drugs (a three or more drug scheme) should be considered the probability of primary hyperaldosteronism.

• In patients < 40 year old with genetic background of hypertension and cardiovascular catastrophes, primary hyperaldosteronism presence should be considered.

• All hypertensive patients with first degree relatives with primary hyperaldosteronism must be studied.

• Incidentaloma concomitant with arterial primary hypertension should be studied for Hyperaldosterism.

• Systemic hypertension with hypokalemia must be considered for primary hyperaldosterism.

• Primary aldosterism treatment may be pharmacological or surgical according to etiology.

• All patients treated pharmacologically or surgically must undergo a continual follow up for several years owing to the toxic sequels of aldosterone.

REFERENCIAS

1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45: 1243-1248. [ Links ]

2. Sasano H, Nakamura Y, Moriya T, Suzuki T. Adrenal cortex. Endocrine Pathology Differential Diagnosis and Molecular Advances. Second edition. New York, USA: Springer; 2009. p. 211-226. [ Links ]

3. Sang X, Jiang Y, Wang W, Yan L, Zhao J, Peng Y et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens. 2013; 31: 1465-1471. [ Links ]

4. Moraitis A, Stratakis C. Adrenocortical causes of hypertension. Int J Hypertens. 2011; 201: 1-10. [ Links ]

5. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, et al Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994; 121: 877-885. [ Links ]

6. Hirohara D, Nomura K, Okamoto T, Ujihara M, Takano K. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab. 2001; 86: 4292-4298. [ Links ]

7. Funder JW, Carey RM, Fardella C, Gomez-Sanchez C, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93: 3266-3281. [ Links ]

8. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens. 2006; 24: 737-745. [ Links ]

9. Rossi GP, Belfiore A, Bernini G. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens. 2007; 25: 1433-1442. [ Links ]

10. Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab. 2014; 99: 2745-2753. [ Links ]

11. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens. 2002; 15: 896-902. [ Links ]

12. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension. 2001; 37: 1440-1443. [ Links ]

13. Castro OL, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension. 2002; 39: 935-938. [ Links ]

14. Patel SM, Lingam RK, Beaconsfield TI, Tran TL, Brown B. Role of radiology in the management of primary aldosteronism. Radiographics. 2007; 27: 1145-1157. [ Links ]

15. Umachi F, Marzola MC, Zucchetta P, Tregnaghi A, Cecchin D, Favia G et al. Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value radiocholesterol scintigraphy, CT scan and MRI. Nucl Med Commun. 2003; 24: 683-688. [ Links ]

16. Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab. 2001; 86: 1066-1071. [ Links ]

17. Doppman JL, Gill JR Jr. Hyperaldosteronism: sampling the adrenal veins. Radiology. 1996; 198: 309-312. [ Links ]

18. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005; 1: 143-158. [ Links ]

19. Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens. 2010; 23: 1253-1260. [ Links ]

20. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004; 136: 1227-1235. [ Links ]

21. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007; 50: 911-918. [ Links ]

22. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006; 295: 2638-2645. [ Links ]

23. Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone, and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011; 29: 980-990. [ Links ]

24. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens. 2001; 19: 353-361. [ Links ]

25. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol. 2007; 66: 607-618. [ Links ]

26. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001; 135: 258-261. [ Links ]

27. Milsom SR, Espiner EA, Nicholls MG, Gwynne J, Perry EG. The blood pressure response to unilateral adrenalectomy in primary aldosteronism. Q J Med.1986; 61: 1141-1151. [ Links ]

28. Chiang WF, Cheng CJ, Wu ST, Sun GH, Lin MY, Sung CC, et al. Incidence and factors of post-adrenalectomy hyperkalemia in patients with aldosterone producing adenoma. Clin Chim Acta. 2013; 424: 114-118. [ Links ]

29. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. Ren Angioten Aldoster Syst. 2001; 2: 156-169. [ Links ]

30. Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg. 2005; 29: 155-159. [ Links ]

Nota

Este artículo puede ser consultado en versión completa en: http://www.medigraphic.com/revmexcardiol